RC 906 - Translational research in molecular imaging: how to do the translation
RC 906 - Translational research in molecular imaging: how to do the translationFriday, March 3, 08:30 - 10:00 Room: M 3 Session Type: Refresher Course Topics: Nuclear Medicine, Physics in Medical Imaging, Education, Molecular Imaging Moderator: J. Hodler (Zurich/CH) Add session to my schedule In your schedule (remove)
1. To learn the translational potential of preclinical research.
2. To understand the needs of preclinical research.
3. To know the physiological differences between small animals and humans.
Radiologists are good organisers with excellent knowledge of technology and with an important role in patient care. They are not necessarily at the forefront of basic research. Although radiologists do not all need to perform animal studies, we need to understand methodology, to recognize new findings with clinical potential and to reduce the well-known time lag between “bench and bedside”. This session contributes knowledge about preclinical imaging and its translation into clinical radiology by experts in their fields.
1. To learn the use of preclinical PET/MR imaging.
2. To understand the needs of standardisation in preclinical imaging.
3. To understand the challenges in quantitative preclinical PET imaging.
Small animal molecular imaging has become an important technique for the development of new drugs, radiotracers and therapies. Positron emission tomography (PET) together with magnetic resonance imaging (MRI) provides unique in vivo information about specific molecular pathways in different diseases. How to decide what settings or conditions to use is not straightforward, as the experimental design is dependent on the particular science being investigated. In small animal imaging there are different multi-modal techniques available starting from using two stand-alone scanners to fully integrated PET/MRI scanners. From physics to physiology, there are many factors to consider when setting up an experiment, each of which can have a significant impact upon quantitative PET/MRI data. Standardization from animal models, animal handling, data acquisition protocols, and image data analysis should help to generate data that can be reproduced by the same or other laboratories to enhance scientific importance. This talk examines the most common factors related to all types of quantitative PET imaging.
1. To understand advantages and limitations of nanomedicines.
2. To gain knowledge on elimination routes of nanoprobes.
3. To understand the potential benefit of active targeting.
The design of a molecular imaging agent should follow its clinical demands. This sounds trivial but often basic questions are not asked, which leads to failure in translation. Therefore, the following questions should be answered positively before starting research and development: is there a clinical need for the envisioned diagnostic procedure? Does its application impact the therapeutic conduct? Are all alternative drug designs less promising? Will the agent fulfil the required pharmacokinetic demands? Are toxic side effects not expected? Is the imaging method sufficiently robust and sensitive to draw a clear conclusion from the application of the nanodiagnostic agent also when analysing individual patients instead of comparing groups? Is there sufficient market potential for commercialisation and can the production be controlled and upscaled? Asking these questions will substantially help researchers to find ideal indication for nanomedicines and nanodiagnostics. For example, if fast compartmental exchange and renal clearance are required, the nanoparticles must be below 5 nm. If EPR-dependent accumulation is desired, the particles should be larger but neutrally charged. In turn, charged particles are preferred for labelling the MPS (mononuclear phagocyte system) and cells in vitro. Active targeting, may be used to enhance local retention and cellular uptake but it will not improve (even rather decrease) accumulation due shortening blood half-life. Using examples of our and others research on nanodiagnostics, nanotherapeutics and theranostics, the above questions will be addressed and according concepts and their strengths and limitations will be explained and discussed in detail.
1. To learn the benefits of preclinical imaging for clinical activities.
2. To learn how to translate the knowledge from preclinical to clinical applications.
3. To understand the limitations of translation.
"no abstract submitted"